ATE288745T1 - Transdermal verabreichungssystem für die behandlung von harnwegserkrankungen - Google Patents

Transdermal verabreichungssystem für die behandlung von harnwegserkrankungen

Info

Publication number
ATE288745T1
ATE288745T1 AT01121687T AT01121687T ATE288745T1 AT E288745 T1 ATE288745 T1 AT E288745T1 AT 01121687 T AT01121687 T AT 01121687T AT 01121687 T AT01121687 T AT 01121687T AT E288745 T1 ATE288745 T1 AT E288745T1
Authority
AT
Austria
Prior art keywords
group
substituted
alkyl
phenyl
halogen atoms
Prior art date
Application number
AT01121687T
Other languages
English (en)
Inventor
Frank Dr Dressen
Dietrich Schacht
Hans-Michael Dr Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh, Kissei Pharmaceutical filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE288745T1 publication Critical patent/ATE288745T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01121687T 2001-09-14 2001-09-14 Transdermal verabreichungssystem für die behandlung von harnwegserkrankungen ATE288745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01121687A EP1293198B1 (de) 2001-09-14 2001-09-14 Transdermal Verabreichungssystem für die Behandlung von Harnwegserkrankungen

Publications (1)

Publication Number Publication Date
ATE288745T1 true ATE288745T1 (de) 2005-02-15

Family

ID=8178599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01121687T ATE288745T1 (de) 2001-09-14 2001-09-14 Transdermal verabreichungssystem für die behandlung von harnwegserkrankungen

Country Status (9)

Country Link
US (1) US20050226919A1 (de)
EP (1) EP1293198B1 (de)
AT (1) ATE288745T1 (de)
DE (1) DE60108870T2 (de)
DK (1) DK1293198T3 (de)
ES (1) ES2237515T3 (de)
HK (1) HK1054327B (de)
PT (1) PT1293198E (de)
WO (1) WO2003024432A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006038619A1 (ja) * 2004-10-06 2008-05-15 キッセイ薬品工業株式会社 前立腺肥大症に対する手術療法への移行予防用医薬組成物
DE602006003813D1 (de) * 2005-06-06 2009-01-08 Fujimoto Co Ltd Pharmazeutische Zusammensetzung zur perkutane Absorption unter Verwendung von einem Metalchlorid, vorzugsweise Natriumchlorid, zur Vorbeugung von Kohäsionsschwäche
US20130211353A1 (en) * 2010-10-28 2013-08-15 Hisamitsu Pharmaceutical Co., Inc. Percutaneous absorption type formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP19991583B (en) * 1991-06-10 1999-04-29 Sanol Arznei Schwarz Gmbh Nitroglycerine Plaster and Method for Its Production
DE122010000031I1 (de) * 1992-12-02 2010-10-21 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
US5843472A (en) * 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
AU3011299A (en) * 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists

Also Published As

Publication number Publication date
HK1054327B (zh) 2005-07-29
DE60108870D1 (de) 2005-03-17
PT1293198E (pt) 2005-06-30
DE60108870T2 (de) 2005-07-28
US20050226919A1 (en) 2005-10-13
EP1293198B1 (de) 2005-02-09
EP1293198A1 (de) 2003-03-19
ES2237515T3 (es) 2005-08-01
DK1293198T3 (da) 2005-06-06
WO2003024432A3 (en) 2003-09-04
HK1054327A1 (en) 2003-11-28
WO2003024432A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
ATE384524T1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
NL300175I2 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DE60233884D1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
PE20040728A1 (es) Inhibidores de caspasa
ATE468109T1 (de) Liposomale abgabe von verbindungen auf vitamin-e- basis
FI954243A0 (fi) Farmaseuttiset yhdisteet
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE357453T1 (de) Comt-inhibitoren
ATE288745T1 (de) Transdermal verabreichungssystem für die behandlung von harnwegserkrankungen
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
KR970706811A (ko) I형 알레르기성 질환의 예방 및 치료제(Preventive and remedy for type Ⅰ allergic diseases)
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
ATE511395T1 (de) Mittel zur behandlung von glomerulopathie
ATE250413T1 (de) 2-aminotetraline zur behandlung von glaukom
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
DE60223936D1 (de) Mittel zur anregung des appetits und mittel zur behandlung von anorexie
ATE225785T1 (de) Tetrazolylalkyl-indolderivate als entzündungshemmende und analgetische mittel
EA199900570A1 (ru) Гипоталамо-гипофизарное средство, вызывающее устойчивую стадию торможения и/или покоя у собак и стадию покоя у кошек (анэструс)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1293198

Country of ref document: EP

EEIH Change in the person of patent owner